Pasithea Therapeutics (KTTA) Equity Ratio (2020 - 2026)

Pasithea Therapeutics' Equity Ratio history runs 7 years deep, the most recent figure standing at 0.97 for Q1 2026.

• In Q1 2026, Equity Ratio rose 9.85% year-over-year to 0.97; the TTM figure through Mar 2026 stood at 0.97 (up 9.85% YoY), while the FY2025 annual figure was 0.92, changed 0.38% from the prior year.
• Equity Ratio came in at 0.97 for Q1 2026 at Pasithea Therapeutics, up from 0.92 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2022 to a low of 0.89 in Q1 2025.
• A 5-year average of 0.93 and a median of 0.93 in 2023 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio rose 20.46% in 2022 and decreased 6.3% in 2025, its largest moves.
• Pasithea Therapeutics' Equity Ratio stood at 0.94 in 2022, then declined by 4.75% to 0.9 in 2023, then rose by 2.71% to 0.92 in 2024, then fell by 0.38% to 0.92 in 2025, then increased by 6.11% to 0.97 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.97, 0.92, and 0.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison